


Newsletter June 2014

How can you use disease specific indicators to refine your patient population?

The General Practitioner (GP) Database, included in the PHARMO Database Network, contains diagnoses, symptoms and other clinical parameters. These parameters help to characterize disease specific indicators, which allow for distinction between types of diseases (e.g. type I and II diabetes mellitus, COPD and asthma, etc.) or within one type of disease (e.g. between severities). Learn more about the Pharmo GP Database.

For example, FEV₁-measurement/GOLD stage determines severity of COPD. These disease specific indicators can be extracted from the PHARMO GP Database. Instead of only calculating the exacerbation (recurrence) rate among all patients using respiratory medication, a distinction can now be made between asthma and COPD patients, but also between different GOLD stages among COPD patients (see Figure 1).

Want to know more? Check the soon to be published article: Overbeek et al., Burden of exacerbations in patients with moderate to very severe COPD in the Netherlands: a real-life study, COPD, accepted.



 $\label{thm:condition} \textbf{Figure 1: Exacerbation recurrence rates among COPD patients, total and stratified by GOLD. }$

The PHARMO GP Database is expanding and currently includes more than 400 practices, which serve approximately 2 million patients. For more information, please visit www.pharmo.com or call us at +31 30 7440 800.

Did you know?

The PHARMO Institute maintains a large and high quality Database Network and works closely with (inter)national medical universities and European databases for studies with longitudinal and real-life patient data. PHARMO services provide solutions for decision makers in market access, health economics and health outcomes domains. Learn more about how we can assist you with your research questions. Contact us for a teleconference to find the solution that works best for your business.

